HEATHER WHITTAKER: Open Payments
NPI 1235821141 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,311 in 65 payments from 18 companies in 2025. Trend: 2023 $761 · 2024 $1,610 · 2025 $1,311
Food & beverage: $1,311
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $352 |
| Lilly USA, LLC | 9 | $175 |
| ABBVIE INC. | 8 | $148 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $97 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $89 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $71 |
| PFIZER INC. | 4 | $69 |
| Lundbeck LLC | 2 | $46 |
| AstraZeneca Pharmaceuticals LP | 2 | $44 |
| Merck Sharp & Dohme LLC | 2 | $43 |
Products named: MOUNJARO, Rybelsus, JARDIANCE, Wegovy, Ozempic, CAPLYTA, XIFAXAN, VRAYLAR.
Industry payments across MD — which companies pay providers there.
